News and Updates

Learn about the people making the CATT1 clinical trial happen, the science behind cadisegliatin for type 1 diabetes, and how to get involved.

Analysis compiled by Avalere Health and supported by Breakthrough T1D (formerly JDRF) finds that research funded by the Special Diabetes Program (SDP) has yielded more than $50 billion in federal healthcare savings.  Created by Congress in 1997 and administered by the National Institutes of Health (NIH), the SDP provides federal funding to support research to prevent, treat, and […]

Continuous glucose monitors have been transformative for daily type 1 diabetes management. Can they benefit people without diabetes?

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

Menstrual cycles and type 1 diabetes (T1D) have a lot in common: they can be unpredictable, inconsistent from person to person, and physically challenging. For Women’s Health Month, Breakthrough T1D is taking a closer look at how periods and menopause may influence blood sugar. What happens during the menstrual cycle? Most girls get their first […]

Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.

While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D.   This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D.   Here are the […]

Update – November 22, 2024 This morning, Lexicon Pharmaceuticals, Inc. (Lexicon) announced they received a “deficiencies preclude discussion” letter from the FDA regarding this drug application. The FDA is not approving sotagliflozin for use in glucose control in people with T1D and CKD and there will be no further discussion in regards to this application.  […]

A T1D dad and physician's POV about the start of a new school year.

At the ADA Scientific Sessions, scientists will present the latest T1D research, all with the goal of improving lives for the T1D community.